- Home
- TBPH vs MFH Comparison
TBPH vs MFH Comparison
Compare TBPH & MFH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBPH
- MFH
- Stock Information
- Founded
- TBPH 2013
- MFH 2011
- Country
- TBPH United States
- MFH United States
- Employees
- TBPH N/A
- MFH N/A
- Industry
- TBPH Biotechnology: Pharmaceutical Preparations
- MFH Finance: Consumer Services
- Sector
- TBPH Health Care
- MFH Finance
- Exchange
- TBPH Nasdaq
- MFH Nasdaq
- Market Cap
- TBPH 464.5M
- MFH 372.5M
- IPO Year
- TBPH N/A
- MFH N/A
- Fundamental
- Price
- TBPH $8.91
- MFH $5.98
- Analyst Decision
- TBPH Buy
- MFH
- Analyst Count
- TBPH 3
- MFH 0
- Target Price
- TBPH $11.33
- MFH N/A
- AVG Volume (30 Days)
- TBPH 268.3K
- MFH 99.3K
- Earning Date
- TBPH 05-08-2025
- MFH 05-23-2025
- Dividend Yield
- TBPH N/A
- MFH N/A
- EPS Growth
- TBPH N/A
- MFH N/A
- EPS
- TBPH N/A
- MFH N/A
- Revenue
- TBPH $65,266,000.00
- MFH $1,007,430.00
- Revenue This Year
- TBPH $51.09
- MFH N/A
- Revenue Next Year
- TBPH N/A
- MFH N/A
- P/E Ratio
- TBPH N/A
- MFH N/A
- Revenue Growth
- TBPH 6.11
- MFH 125.92
- 52 Week Low
- TBPH $7.44
- MFH $1.03
- 52 Week High
- TBPH $10.90
- MFH $8.86
- Technical
- Relative Strength Index (RSI)
- TBPH 40.95
- MFH 46.29
- Support Level
- TBPH $8.69
- MFH $5.30
- Resistance Level
- TBPH $10.55
- MFH $6.68
- Average True Range (ATR)
- TBPH 0.38
- MFH 0.81
- MACD
- TBPH -0.12
- MFH -0.12
- Stochastic Oscillator
- TBPH 12.06
- MFH 26.15
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
About MFH Mercurity Fintech Holding Inc.
Mercurity Fintech Holding Inc is a New York-based digital fintech leader providing access to the rapidly growing AI-powered infrastructure, blockchain, and digital assets sectors. Its three core business lines include: 1. Blockchain and digital asset solutions. 2. AI and HPC infrastructure, specializing in developing liquid cooling solutions for AI data centers. 3. Comprehensive financial services.